Allarity Therapeutics

Allarity Therapeutics reported a total Q2 loss of $3.7m versus $4.2m a year earlier, with cash and cash equivalents of $26.9m. Research and administrative expenses each fell to $1.3m, and the production campaign for stenoparib was completed early; related payments were recorded as prepaid expenses. The US Patent Office granted a patent for the stenoparib companion diagnostic “Drug Response Predictor” with protection through April 2042, and the Hørsholm laboratory received CLIA registration for internal testing in the US. At AACR, Allarity presented Phase 2 data showing extended overall survival in certain patients with platinum‑resistant ovarian cancer; recruitment continues for several Phase 2 studies, including a VA‑funded trial in small cell lung cancer. » Más en de.investing.com